NYSEAMERICAN:VTAK

Catheter Precision Q3 2026 Earnings Results & Report

Catheter Precision logo
$0.15 0.00 (0.00%)
As of 10/9/2026

Catheter Precision beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$8.16 versus the -$13.30 consensus estimate, while revenue of $1.84 million fell short of the $2.80 million estimate by $962.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

Catheter Precision EPS Results

Actual EPS
-$8.16
Consensus EPS
-$13.30
Beat/Miss
Beat by +$5.14
One Year Ago EPS
N/A

Catheter Precision Revenue Results

Actual Revenue
$1.84 million
Expected Revenue
$2.80 million
Beat/Miss
Missed by -$962.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Catheter Precision Q3 2026 Earnings FAQ

Catheter Precision (NYSEAMERICAN:VTAK) reported earnings of -$8.16 per share for Q3 2026, beating the consensus estimate of -$13.30. The report was announced on Monday, November 16, 2026.

Catheter Precision reported revenue of $1.84 million for Q3 2026, against a consensus estimate of $2.80 million.

Catheter Precision Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Catheter Precision Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catheter Precision? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catheter Precision and other key companies, straight to your email.

About Catheter Precision

Catheter Precision (NYSEAMERICAN:VTAK) is a medical technology company focused on products for electrophysiology, the specialty concerned with diagnosing and treating abnormal heart rhythms. Its products are designed to support clinicians during procedures involving cardiac arrhythmias.

The company’s VIVO system uses patient-specific imaging and electrical data to create a three-dimensional view of the heart and help clinicians locate the source of ventricular arrhythmias before ablation procedures. Catheter Precision also offers LockeT, a device intended to assist with closure of femoral venous access sites after procedures.

Catheter Precision’s product portfolio reflects its focus on tools for planning and supporting electrophysiology procedures. Its shares trade on the NYSE American under the symbol VTAK.

View Catheter Precision Profile